Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
Details· CHMP positive opinion is based on a robust analytical,non-clinical and clinical data package comparing USYMRO ® to the reference product Stelara ® Guangzhou,China– June , 2024 – Bio-TheraSolutions Inc. (688177:SH),a commercial-stage biopharmaceutical company developing a pipeline ofinnovati...
Download Poster_Safety and efficacy of BAT8006, a folate receptor α (FRα) antibody drug conjugate, in patients with platinum-resistant ovarian cancer: Update on the dose optimization/expansion cohort of BAT-8006-001-CR trial. Download Poster_BAT8008, a Trop-2 antibody-drug conjugate (ADC), in pati...
Guangzhou and London – May 22, 2025 – Bio-Thera Solutions,Ltd (688177:SH), a commercial-stage biopharmaceutical company developing apipeline of biosimilars and innovative assets and Hikma Pharmaceuticals PLC,along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. today announcedtha...
